Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Korábbi kezelés

• Any previous autologous HSCT must have occurred at least 3 months prior to start of conditioning.
• No previous allogeneic HSCT.

Más betegség

• No active extramedullary leukemia or known active CNS involvement by malignancy.
• No uncontrolled infection.
• No known HIV infection.
• No active replicating HBV or HCV infection detected by PCR that requires treatment or at risk for HBV reactivation (positive HBsAg)

Egyéb

• Not pregnant or breast-feeding

• Presence of a suitable related, HLA-haploidentical (partially mismatched) stem cell donor.
• Eligible diagnoses:
  • Acute leukemias in complete remission with minimal residual disease
  • Myelodysplastic syndrome (MDS) with at least one poor-risk feature
  • Chronic myelomonocytic leukemia with at least one poor-risk feature
  • T-cell PLL in PR or better prior to transplantation.
  • Tyrosine kinase-refractory CML in first chronic phase, TKI-intolerant CML in first chronic phase, or CML in second or subsequent chronic phase.
  • Philadelphia chromosome negative myeloproliferative disease (including myelofibrosis)
  • Multiple myeloma or plasma cell leukemia with a PR or better to the last treatment regimen
• Age ≥ 60 years.
• Adequate end-organ function as measured by:
  • Left ventricular ejection fraction ≥ 35% or shortening fraction > 25%
  • Bilirubin ≤ 3.0 mg/dL (unless due to Gilbert's syndrome or hemolysis), and ALT and AST ≤ 5 x ULN
  • FEV1 and FVC ≥ 40% of predicted
• ECOG performance status ≤ 2 or Karnofsky score ≥ 60